Correctsequence
Shanghai, CN · 2 known investors
CorrectSequence Therapeutics develops base-editing gene therapies using its proprietary transformer Base Editor (tBE) platform to treat genetic diseases, rare diseases, and common conditions including inherited disorders, metabolic diseases, cardiovascular diseases, and cancers. The company has advanced multiple pipeline candidates into clinical and investigational stages, including programs for β-thalassemia and sickle cell disease.
Founders & leadership
陈
陈佳Founding Professor / Chief Scientific Advisor
牟
牟晓盾Chief Executive Officer
Investors · 2
Frequently asked questions
- What does Correctsequence do?
- CorrectSequence Therapeutics develops base-editing gene therapies using its proprietary transformer Base Editor (tBE) platform to treat genetic diseases, rare diseases, and common conditions including inherited disorders, metabolic diseases, cardiovascular diseases, and cancers. The company has advanced multiple pipeline candidates into clinical and investigational stages, including programs for β-thalassemia and sickle cell disease.
- Who founded Correctsequence?
- Correctsequence was founded by 陈佳.
- Who are Correctsequence's investors?
- Correctsequence's investors include LAV, Lilly Asia Ventures.
- Where is Correctsequence headquartered?
- Correctsequence is headquartered in Shanghai, CN.